Coave Collaborated with Institute of Neurodegenerative Diseases to Develop Gene Therapy for Neurodegenerative Disorders
Shots:
- Coave & IMN collaborated to develop gene therapy programs targeting protein degradation for neurodegenerative disorders. The collaboration will use Coave’s AAV-Ligand Conjugate (ALIGATER) platform to design, develop and manufacture coAAV viral vectors expressing the TFEB gene for specific delivery to deep brain areas
- The collaboration focuses on gene therapy products targeting TFEB for alpha-synucleinopathies incl. MSA and idiopathic PD
- IMN will be responsible for in vivo studies to evaluate the effect of gene therapy products in animal models of MSA and PD. The collaboration plans to provide in vivo proof of concept data & a selection of therapeutic candidates in IND enabling studies
Ref: PRNewswire | Image: Coave
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
